Rational Approaches to Improving Selectivity in Drug Design

• Main Authors: Huggins, David J. (Author), Sherman, Woody (Author), Tidor, Bruce (Contributor)
• Other Authors: Massachusetts Institute of Technology. Computer Science and Artificial Intelligence Laboratory (Contributor), Massachusetts Institute of Technology. Department of Electrical Engineering and Computer Science (Contributor), Whitehead Institute for Biomedical Research (Contributor)
• Format: Article
• Language: English
• Published: American Chemical Society (ACS), 2012-10-02T15:15:23Z.
• Subjects: Article
• Online Access: Get fulltext

 Appropriate tuning of binding selectivity is a primary objective in the discovery and optimization of a compound on the path toward developing a drug. The environment in which drugs act is complex, with many potential interaction partners. Proteins, DNA, RNA, lipids, sugars, metabolites, and other small molecules all have the potential to interact with a drug, and in many cases these unexpected interactions lead to undesired and often severe side effects. Conversely, the ability to interact with multiple targets or drug resistance mutants can be advantageous in certain contexts. Designing a drug with the appropriate balance of avoidance of undesirable targets (narrow selectivity) and coverage of one or more targets of interest (broad selectivity, also referred to as promiscuity) is a continual drug development challenge. In many cases this objective is attained through trial and error, but there are rational approaches that can guide the tuning of selectivity, and examples have been published that illustrate a number of generalizable strategies. In this review, we discuss fundamental principles that account for selectivity and highlight examples where selectivity has been attained through rational design. An understanding of the general principles that drive selectivity should allow for more efficient design of compounds with desirable selectivity profiles.